PCRX
Pacira BioSciences, Inc.
-0.09 (-0.36%)24.82USD73.9K成交股數989M市值68.9本益比(近四季)1.3股價營收比+6.2%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 192M+14% | 177M-5% | 180M+6% | 181M+2% | 169M+1% | 187M+14% | 169M-1% | 178M+11% | 167M | 164M | 169M | 160M |
| 營業成本 | 44.2M | 36.4M | 34.3M | 40.9M | 34.3M | 39.9M | 38.9M | 44.3M | 47.4M | 39.8M | 48.2M | 49.0M |
| 毛利 | 148M+10% | 141M-4% | 145M+12% | 140M+5% | 135M+12% | 147M+19% | 130M+7% | 134M+20% | 120M | 124M | 121M | 111M |
| 毛利率 | 77.0% | 79.5% | 80.9% | 77.4% | 79.7% | 78.7% | 76.9% | 75.1% | 71.6% | 75.8% | 71.6% | 69.4% |
| 研發費用 | 30.2M | 28.1M | 26.0M | 28.2M | 25.3M | 23.9M | 19.1M | 20.3M | 18.2M | 20.8M | 18.8M | 17.1M |
| 銷售管理費用 | 91.8M | 93.9M | 91.8M | 88.6M | 86.8M | 79.6M | 74.3M | 68.1M | 72.0M | 67.9M | 64.9M | 70.8M |
| 營業利益 | 4.3M+114% | 6.9M-72% | 6.4M-105% | 8.5M-70% | 2.0M-85% | 24.7M+39% | −140M-450% | 28.2M-1014% | 13.2M | 17.7M | 39.9M | −3.1M |
| 營業利益率 | 2.2% | 3.9% | 3.5% | 4.7% | 1.2% | 13.2% | -82.8% | 15.9% | 7.9% | 10.8% | 23.5% | -1.9% |
| 稅後淨利 | 4.7M-3% | 2.9M-82% | 5.4M-104% | −4.8M-126% | 4.8M-46% | 16.0M+47% | −143M-657% | 18.9M-197% | 9.0M | 10.9M | 25.8M | −19.5M |
| 淨利率 | 2.4% | 1.6% | 3.0% | -2.7% | 2.8% | 8.5% | -85.1% | 10.6% | 5.4% | 6.6% | 15.2% | -12.2% |
| 稀釋 EPS | 0.12+20% | 0.07-82% | 0.12-104% | -0.11-128% | 0.10-47% | 0.38+65% | -3.11-710% | 0.39-191% | 0.19 | 0.23 | 0.51 | -0.43 |
| 稀釋股數 | 40.3M | 40.9M | 44.5M | 45.5M | 46.5M | 46.2M | 46.1M | 50.5M | 52.2M | 52.1M | 52.1M | 45.9M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 206M | 144M | 148M | 300M | 284M | 277M | 246M | 247M | 184M | 99.1M | 86.8M | 35.5M |
| 應收帳款 | 132M | 126M | 115M | 114M | 105M | 113M | 101M | 105M | 102M | 97.0M | 99.1M | 93.2M |
| 存貨 | 135M | 150M | 158M | 148M | 134M | 125M | 112M | 103M | 96.8M | 96.5M | 92.1M | 93.0M |
| 總資產 | 1.2B | 1.2B | 1.3B | 1.5B | 1.6B | 1.6B | 1.5B | 1.6B | 1.6B | 1.5B | 1.5B | 1.5B |
| 有息負債 | 363M | 368M | 377M | 580M | 583M | 384M | – | – | – | – | – | – |
| 總負債 | 572M | 555M | 570M | 779M | 788M | 775M | 772M | 768M | 691M | 703M | 734M | 755M |
| 股東權益 | 672M | 654M | 727M | 758M | 799M | 778M | 750M | 879M | 892M | 832M | 808M | 768M |
| 負債比 | 46.0% | 45.9% | 44.0% | 50.7% | 49.7% | 49.9% | 50.7% | 46.6% | 43.7% | 45.8% | 47.6% | 49.6% |
| 淨現金(現金 − 有息負債) | −157M | −223M | −229M | −280M | −300M | −107M | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 25.7M | – | – | 35.5M-28% | – | – | – | 49.1M | – | – | 19.1M |
| 資本支出 | – | 2.7M | – | – | 8.5M | – | – | – | 2.8M | – | – | 6.6M |
| 自由現金流 | – | 23.0M | – | – | 26.9M-42% | – | – | – | 46.3M | – | – | 12.6M |
| 折舊攤銷 | – | 21.3M | – | – | 21.2M | – | – | – | 18.4M | – | – | 19.6M |
| 買回庫藏股 | – | 50.0M | – | – | 0.00 | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 12.9% | – | – | 15.9% | – | – | – | 27.7% | – | – | 7.8% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 726M
| Reportable | 726M | 100.0% | +3.6% |
|---|
產品／服務2025 年度 · 726M
| EXPAREL | 575M | 79.2% | +4.8% |
|---|---|---|---|
| ZILRETTA | 117M | 16.1% | -1.2% |
| Iovera | 24.2M | 3.3% | +6.0% |
| Bupivacaine Liposome Injectable Suspension | 6.9M | 1.0% | -5.6% |
| Royalty | 3.6M | 0.5% | -5.9% |
| 產品 小計 | 723M | 99.5% | +3.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 726M | +3.6% | 7.0M | 1.0% | 0.16 | 137M |
| FY2024 | 701M | +3.9% | −99.6M | -14.2% | -2.15 | 179M |
| FY2023 | 675M | +1.2% | 42.0M | 6.2% | 0.89 | 139M |
| FY2022 | 667M | +23.1% | 15.9M | 2.4% | 0.34 | 115M |
| FY2021 | 542M | +26.0% | 42.0M | 7.8% | 0.92 | 79.9M |
| FY2020 | 430M | +2.6% | 146M | 33.9% | 3.33 | 39.2M |
| FY2019 | 419M | +26.0% | −11.0M | -2.6% | -0.27 | 60.4M |
| FY2018 | 332M | – | −471K | -0.1% | -0.01 | 34.4M |